Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading on Wednesday after an insider sold shares in the company. $286.19 million flowed into the stock on the tick-up and $139.67 million flowed out of the stock on the tick-down, for a money net flow of $146.52 million into the stock. Of all stocks tracked, Johnson & Johnson had the 4th highest net in-flow for the day. Johnson & Johnson traded down ($0.96) for the day and closed at $129.91Specifically, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.19% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research note on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Finally, Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $146.16.
The firm has a market cap of $349,010.00, a P/E ratio of 333.10, a P/E/G ratio of 2.23 and a beta of 0.74. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
A number of large investors have recently modified their holdings of JNJ. Armstrong Henry H Associates Inc. lifted its holdings in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Armstrong Henry H Associates Inc. now owns 497,392 shares of the company’s stock worth $65,800,000 after acquiring an additional 4,306 shares during the last quarter. Steinberg Global Asset Management lifted its holdings in shares of Johnson & Johnson by 4.7% in the 2nd quarter. Steinberg Global Asset Management now owns 25,214 shares of the company’s stock worth $3,336,000 after acquiring an additional 1,123 shares during the last quarter. Bristlecone Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.0% in the 2nd quarter. Bristlecone Advisors LLC now owns 27,275 shares of the company’s stock worth $3,608,000 after acquiring an additional 257 shares during the last quarter. First Heartland Consultants Inc. lifted its holdings in shares of Johnson & Johnson by 27.6% in the 2nd quarter. First Heartland Consultants Inc. now owns 20,488 shares of the company’s stock worth $2,710,000 after acquiring an additional 4,428 shares during the last quarter. Finally, Park Avenue Securities LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $1,221,000. 65.58% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/21/investors-buy-johnson-johnson-jnj-on-weakness-following-insider-selling.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.